SOUTH SAN FRANCISCO, Calif.,
Nov. 9, 2020 /PRNewswire/
-- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical
company developing new generation medicines for anxiety, depression
and other central nervous system (CNS) disorders, today announced
that senior management will participate in the Guggenheim
Healthcare Talks, Idea Forum, 2nd Annual
Neuro/Immunology Day, a virtual event focused on both established
and emerging companies in the neurological and immunological
disease spaces, as well as salient thematic topics of interest to
investors, taking place on Monday, November
16, 2020.
About VistaGen
VistaGen Therapeutics, Inc. is a
clinical-stage biopharmaceutical company committed to developing
and commercializing differentiated new generation medications that
go beyond the current standard of care for anxiety, depression and
other CNS disorders. Each of VistaGen's three drug candidates has a
differentiated mechanism of action, an exceptional safety profile
in all studies to date, and therapeutic potential in multiple CNS
markets. For more information, please visit www.vistagen.com and
connect with VistaGen on Twitter, LinkedIn and Facebook.
Forward Looking Statements
Various statements in this
release are "forward-looking statements" concerning VistaGen's
future expectations, plans and prospects. These forward-looking
statements are neither promises nor guarantees of future
performance, and are subject to a variety of risks and
uncertainties which could cause actual results to differ materially
from those contemplated in these forward-looking statements,
including the risks that: development and approval of one or
more of the Company's drug candidates may not be achieved in any
market, and, if approved, may not be differentiated from the
standard of care; the FDA and other regulatory authorities may
decide that the results of one or more of the Company's development
programs are not sufficient for regulatory approval; development of
the Company's drug candidates may not be successful in any
indication; success in nonclinical studies or in earlier-stage
clinical studies may not be repeated or observed in future studies;
and other adverse events or market conditions may be encountered,
at any stage of development, that negatively impact further
development, including entry of competitive products or other
technical and unexpected hurdles in the development, manufacture
and commercialization of the Company's drug candidates. Additional
risks are more fully discussed in the section entitled "Risk
Factors" in VistaGen's most recent Annual Report on Form 10-K for
the year ended March 31, 2020, and in
its subsequent quarterly report on Form 10-Q, as well as
discussions of potential risks, uncertainties, and other important
factors in the Company's other filings with the Securities and
Exchange Commission. Any forward-looking statements represent the
Company's views only as of today and should not be relied upon as
representing its views as of any subsequent date. The Company
explicitly disclaims any obligation to update any forward-looking
statements.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/vistagen-therapeutics-to-participate-in-the-guggenheim-healthcare-talks--idea-forum--2nd-annual-neuroimmunology-day-301168440.html
SOURCE VistaGen Therapeutics